Mode
Text Size
Log in / Sign up
N/A N=56 Randomized Single-blind Treatment

Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion

Dental Erosion · Acid Wear

Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Jan 2015
Primary outcome: Primary: Relative Erosion Resistance (RER) of Enamel Specimens Post 4 Hours of Treatment Exposure — -36.66; -36.53; -36.98; -77.82 Percentage RER — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Sodium Fluoride (Drug); Potassium nitrate (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Feb 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Relative Erosion Resistance (RER) of Enamel Specimens Post 4 Hours of Treatment Exposure
-36.66; -36.53; -36.98; -77.82 <0.0001 sig
PRIMARY
Surface Microhardness (SMH) Recovery of Enamel Specimens Post 4 Hours of Treatment Exposure
32.24; 32.32; 34.53; 22.87 <0.0001 sig

Summary

The purpose of this study is to compare and evaluate the ability of two European Union (EU) regulated gel to foam toothpaste formulations versus a non-fluoride toothpaste using a modified in-situ model of dental erosion and remineralization. A positive control i.e fluoride containing toothpaste marketed in EU will also be compared to non-fluoride toothpaste.

Eligibility Criteria

Inclusion Criteria

  • General and Oral Health: Good general health with (in the opinion of the investigator) no clinically OST and OHT examinations.
  • Oral Requirements:
  • An intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch. Subjects may have fixed bridges replacing missing teeth.
  • A gum base stimulated whole saliva flow rate ≥ 0.8 g/min and an unstimulated whole saliva flow rate ≥ 0.2 g/min.
  • Contraception: Women of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.

Exclusion Criteria

  • Oral Health:
  • Current active caries or periodontal disease that may compromise the study or the health of the subjects.
  • Lesions of the oral cavity that could interfere with the study evaluations, including severe gingivitis, grossly carious lesions, periodontitis and other severe periodontal disease.
  • Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Clinical Study/Experimental Medication:
  • Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit
  • Previous participation in this study
  • Substance abuse: Recent history (within the last year) of alcohol or other substance abuse.
  • Pregnancy: Women who are pregnant or who are intending to become pregnant over the duration of the study
  • Breast-feeding: Women who are breast-feeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01657903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search